本文内容均引用权威资料结合个人观点进行撰写，文末已标注文献来源，请知悉。 欧洲的一些政治家已经不隐藏自己的立场了。 去年9月12日，奥地利外长迈因尔-赖辛格接受采访时怂恿称，若中国希望发挥作为全球大国的潜力，避 免卷入欧美领导人提议的进一步制裁，就必须施压俄罗斯停止与乌克兰的冲突。 表面上说是和平，实际上是在重新分配责任，把本应该属于欧洲和北约体系内部的问题推到外面。 这一变化不是突然发生的，随着俄乌冲突时间的延长，欧洲社会、政治上所承受的压力也越来越大。 美国对待调停的态度渐渐趋向于现实主义，欧洲部分国家也开始认识到，美国更关心自身的战略调整和 国内的政治利益，不再关心欧洲的安全体系是否可以恢复稳定。 调停成功与否对美国来说就是外交上的成就，对欧洲来说就是长久安全格局的变化。 但是欧洲并没有公开改变对美国的态度，而是把舆论的焦点转移到中国身上，一些欧洲政治家多次指 出，中国与俄罗斯仍然存在能源交易，从客观上延长了冲突时间。 图 | 美国总统特朗普 但是实际情况比较复杂，美国提出对俄罗斯石油征收重税的时候，欧洲内部并没有达成一致意见，很多 国家担心能源价格会再次波动，态度变得更加谨慎。 矛盾不是偶然的，而是能 ...

Core Points - The article discusses the contradictory statements made by President Trump regarding China's role in the fentanyl crisis, highlighting his fluctuating stance that aligns with trade tariff policies [1][3] - It emphasizes that despite Trump's claims, evidence shows a significant reduction in fentanyl from China since 2019, coinciding with China's strict regulatory measures [3][5] - The article critiques the U.S. healthcare system's failure to address the root causes of the opioid crisis, attributing it to domestic pharmaceutical practices rather than foreign supply [5][7] Summary by Sections U.S.-China Relations and Fentanyl - Trump's comments on China’s efforts to combat fentanyl are inconsistent, reflecting a broader strategy tied to trade tariffs [1] - The signing of the fentanyl trafficking law coincided with Trump's reversion to blaming China for the majority of fentanyl supply [1][3] Impact of China's Regulatory Measures - China's 2019 regulations led to a notable decrease in fentanyl-related deaths in the U.S., with a 20%-25% reduction in overdose fatalities [3][5] - U.S. reports indicate that since 2019, there has been "almost no detection" of fentanyl from China, contradicting Trump's narrative [3][5] Domestic Issues in the U.S. - The article highlights systemic failures in the U.S. healthcare system, where 80% of the world's opioids are consumed by only 5% of the global population [5] - Trump's proposed solutions, such as executing drug traffickers in China, are criticized as superficial and failing to address domestic pharmaceutical lobbying and prescription practices [5][7] - The ongoing opioid crisis in the U.S. is framed as a public health issue that cannot be resolved through political posturing or foreign blame [7]